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The putative oestrogen receptor negative human breast cancer cell line MDA231, when grown as tumours in mice continually
receiving 17b-oestradiol, showed substantially increased growth rate when compared to control animals. Further, we observed
that 17b-oestradiol treatment could both increase the growth rate of established MDA231 tumours as well as decreasing the
time taken for initiating tumour growth. We have also demonstrated that this increase in growth rate is accompanied by a
four-fold increase in nitric oxide synthase activity, which was predominantly the inducible form. Inducible-nitric oxide synthase
expression in these tumours was conﬁrmed by immunohistochemical analysis and appeared localized primarily in areas
between viable and necrotic regions of the tumour (an area that is presumably hypoxic). Prophylactic treatment with the nitric
oxide synthase inhibitor nitro-L-arginine methyl ester resulted in signiﬁcant reduction in this apparent 17b-oestradiol-mediated
growth promoting effect. Tumours derived from mice receiving 17b-oestradiol-treatment were characterized by a signiﬁcantly
lower fraction of perfused blood vessels and an indication of an increased hypoxic fraction. Consistent with these
observations, 17b-oestradiol-treated tumours were less radio-responsive compared to control tumours when treated with a
single radiation dose of 15 Gy. Our data suggests that long-term treatment with oestrogen could signiﬁcantly alter the tumour
oxygenation status during breast tumour progression, thus affecting response to radiotherapy.
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Nitric oxide (NO) acts as an intercellular secondary messenger in
all mammalian organs, participating in a host of functions includ-
ing vascular homeostasis. It is synthesized from L-arginine by a
family of isoenzymes called NO synthases (NOS) (Nathan,
1992). However, its role in tumour biology is complex and still
poorly understood. NO is involved in regulating tumour cell
growth by acting as part of a signalling cascade for neovasculari-
zation in vivo (Jenkins et al, 1995). NO has also been
demonstrated to affect the transcription of certain genes, includ-
ing the vascular endothelial growth factor (VEGF) which is the
basis for angiogenesis associated with tumour growth and metas-
tasis (Folkman, 1995). Growth of solid tumours is regulated by
interactions of several cell types including those of the tumour
vasculature, inﬁltrating immune cells, such as macrophages and
the tumour cells themselves (Sutherland et al, 1988). It has been
shown that elevated levels of NOS are present in human tumours
when compared to surrounding normal tissue and further that
expression is related to tumour grade (Thomsen et al, 1994,
1995; Cobbs et al, 1995).
Previous studies within our laboratories involved manipulating
levels of NO production and hence tumour oxygenation status in
order to gain some understanding of the biochemical and molecu-
lar consequences that the presence of hypoxia imposes on the
biology of solid tumours. We were able to demonstrate that
administration of NOS inhibitors to tumour-bearing mice led to
a signiﬁcant decrease in tumour oxygenation and increase in radia-
tion resistance (Wood et al, 1994a,b). Other workers have used
inhibitors of NOS activity to decrease tumour blood ﬂow (Andrade
et al, 1992) and retard the growth of some experimental tumours
(Thomsen et al, 1997).
Oestrogens are well known to regulate the growth and develop-
ment of normal human mammary tissue (Topper and Freedman,
1980). They have also been implicated in promoting the growth
of most oestrogen-receptor (ER) positive mammary carcinomas
through their mitogenic effects on the cells via these receptors
(McGuire et al, 1975; Dickson and Lippman, 1987). It is proposed
that 17b-oestradiol (E2) enters the target cells and binds to nucle-
ar ER. Following association of the hormone-ER complex with
speciﬁc DNA sequences (oestrogen response elements), the tran-
scription of a speciﬁc set of genes is initiated, leading, among
other events, to increased proliferation. This dependence has been
well documented with the breast tumour cell line, MCF-7, both in
vitro and in vivo (Shaﬁe and Grantham, 1981). Conversely,
MDA231 represents an example of a breast cancer cell line that
has been shown not to transcribe the ER gene (Weigel and
deConnick, 1993). Studies carried out by Friedl and Jordan
(1994), using a subclone of MDA231 tumour cells, demonstrated
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stimulated growth in vivo, thereby suggesting an animal host-
mediated mechanism of action was most likely. NK cells are
lymphocytes that rapidly kill certain tumour cells and are believed
to play an important role in controlling metastases (Kozlowski et
al, 1984; Shakhar and Ben-Eliyahu, 1998). In addition, these
studies as well as that reported by Seaman et al (1978) have
linked suppression of NK activity with chronic administration
of E2. However, the precise role of E2 in suppressing NK cell
activity is still very debatable. For instance, by using a strain of
immunodeﬁcient mice that does not have NK cells, the ﬁndings
of Friedl and Jordan (1994) argued strongly against NK cell-
mediated mechanism of action by E2. A similar view was shared
by other workers who could not demonstrate a correlation
between growth control of human tumours and NK cell activity
in athymic mice with different immune effects (Fodstad et al,
1984). There is now accumulating evidence demonstrating that
E2-treatment can increase the expression of NOS in a wide range
of tissues (Cobbs et al, 1995; Thomsen et al, 1995; Weiner et al,
1994). In this study, we have investigated the effect of long term
E2-treatment on the expression of NOS activity in the putatively
ER-negative human xenograft MDA231 and propose that NO is
an important mediator in promoting this increase in tumour
growth rate. In addition, we have provided some evidence that
demonstrates E2-treatment may alter the oxygenation status of
this tumour type and consequently its radiation response.
MATERIALS AND METHODS
Materials
17b-oestradiol pellets (1.7 mg, 60-day release) were purchased
from Innovative Research of America (Sarasota, USA). NADPH,
Dowex-50WX8-400 and N
o-nitro-L-arginine methyl ester (L-
NAME) were obtained from Sigma (Poole, UK). Tissue culture
medium was obtained from GIBCO-BRL (Paisley, UK) and foetal
calf serum was bought from PAA Laboratories (Wiener Strasse,
Austria). All other reagents were of analytical grade and were
purchased from Sigma (Poole, UK) or otherwise as indicated in
the text.
Cell culture
The MDA231 cells were maintained in exponential growth phase in
RPMI-1640 medium supplemented with 2 mM glutamine and 10%
(v/v) foetal calf serum, in an atmosphere of 5% CO2 in humidiﬁed
air at 378C.
Growth of tumour xenografts
All animal procedures were carried out in accordance with the
Scientiﬁc Procedures Act 1986 and in line with the UKCCCR
guidelines 1999, by approved protocols (Home Ofﬁce Project
Licence No. 40-1770).
Effect of 17b-oestradiol treatment Ten female nu/nu mice were
injected subcutaneously with 2610
6 MDA231 cells on the back in
a volume of 0.1 ml and allowed to grow to about 200 mm
3 in
volume. Half of animals with size-matched tumours were then
treated with E2 pellets (1.7 mg, 60 days release) implanted in the
scruff of the neck and growth measurements were taken until
tumours attained a volume of about 600 mm
3. In another set of
ﬁve animals, E2-treatment was administered 2 days prior to
tumour implantation in order to investigate its effect on the onset
of tumour growth. Measurements were again taken until tumours
attained 600 mm
3. All tumours were excised once they attained the
required growth size and either ﬁxed or snap frozen in liquid
nitrogen for subsequent analysis.
Effect of L-NAME treatment L-NAME was stored frozen at
7208C and added to drinking water and administered ad libitum
(1 mg ml
71) to 10 mice. Treatment commenced 2 days prior to
tumour implantation and continued while growth was monitored
until tumours reached 600 mm
3. Half of these animals also
received E2 pellets (1.7 mg, 60-day release) implanted on the scruff
of the neck.
NOS activity measurements
Snap frozen tumours were thawed and homogenized (Ultra-Turrax
T25 homogenizer) in four volumes of ice-cold buffer containing
HEPES (10 mM, pH 7.4), sucrose (320 mM), EDTA (100 mM),
dithiothreitol (0.05 mM), leupeptin (10 mgm l
71), soybean trypsin
inhibitor (10 mgm l
71) and aprotinin (2 mgm l
71). The prepara-
tions were then sonicated using an MSE Soniprep 150 for 365s
at a nominal frequency of 23 kHz and an oscillation amplitude
of between 5 and 10 mm. Samples were placed in ice between each
sonication. These suspensions were allowed to stand in ice for a
further 10 min, and then centrifuged at 9000 g for 15 min at
48C. The resultant pellet was discarded and the post-mitochondrial
supernatant (cytosol and microsomes) was treated with a strong
cation exchange resin (Dowex-50WX8-400) to remove endogenous
arginine. The supernatant was incubated with the resin for 5 min
and centrifuged at 9000 g for 5 min in order to pellet the resin.
This process was repeated twice, after which the cytosol was treated
as free of endogenous arginine.
Nitric oxide synthase activity was measured by monitoring the
conversion of L-[U-
14C]-arginine to L-[U-
14C]-citrulline. The reac-
tion mixture (ﬁnal volume 150 ml) consisted of HEPES buffer
(20 mM, pH 7.4), L-valine (50 mM), L-citrulline (100 mM), 10 mM
L-arginine and 50 mCi ml
71 l-[U-
14C]-arginine, tetrahydrobiopter-
in (10 mM), calmodulin (400 U ml
71), dithiothreitol (2.5 mM),
calcium chloride (250 mM), bovine serum albumin (75 mg ml
71)
and 1 mM NADPH. The reaction was initiated by the addition of
50 ml of tumour extract (100–300 mg protein) and incubated at
378C for 10 min. The reaction was terminated by the addition of
5 ml of 50% (v/v) Dowex-50WX8-400 resin in water to bind any
remaining arginine. The resin-incubate mix was then left to settle
for 20 min before taking an aliquot of the supernatant for analysis
by scintillation counting. The enzyme activity associated with iNOS
(calcium-independent activity) was measured as a difference in
activity carried in the absence and presence of 1 mM ethylene-
bis-(oxyethylenenitrilo) tetra-acetic acid (EGTA).
Oestrogen receptor (ER) determination
ER determination was carried out in tissue cytosol by employing
a monoclonal antibody kit (ABBOTT ER-EIA Monoclonal, Abbott
Laboratories, Diagnostic Division, Abbott Park, IL, USA). The
sensitivity of the system is calculated as the concentration of
ER that was distinguishable from the zero standard, i.e., two stan-
dard deviations above the zero standard. This was found to
correlate to 1.5 fmol ER mg protein
71 for a cytosol that is
1 mg protein ml
71.
Immunohistochemistry
Tumours were excised and immediately ﬁxed to provide optimum
antigen retrieval and parafﬁn-embedded for immunohistochemical
analysis. Sections were stained with haemotoxylin for cell nuclei.
To visualize iNOS localization on sections, an anti-iNOS polyclonal
antibody (TCS Biologicals Ltd, Bucks, UK) was employed at a dilu-
tion of 5 mgm l
71. After washing off excess primary antibody, this
was followed by incubation with a biotinylated bridging antibody
and an avidin-biotin complex labelled horseradish peroxidase
(Dako Ltd., High Wycombe, Bucks, UK). Following incubation
with 3,3-diaminobenzidine hydrochloride (DAB, Sigma, Poole,
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seen as a dark brown end product.
Analysis of tumour hypoxia, vessel density and perfusion
Tumours that had reached 200 mm
3 in volume from control and
E2-treated groups were treated with 7-(4'-(2-nitroimidazole-1-yl)-
butyl)-theophylline (NITP) 2 h prior to sacriﬁce (140 mg kg
71
in peanut oil containing 10% DMSO). Hoechst 33342 was next
administered 1 min prior to sacriﬁce (20 mg kg
71 in PBS, i.v.
via the tail vein). Mice were culled, tumours rapidly excised, snap
frozen and stored at 7808C.
Immunohistochemical staining and subsequent analytical
procedures were carried out as described elsewhere (Bussink et
al, 1998). Brieﬂy, 5-mm sections were scanned for Hoechst
33342 signal then treated overnight at 48C with rabbit-anti NITP
(anti-theophylline, Sigma, Poole, UK) diluted 1:10 in 9F1 super-
natant (rat anti-mouse endothelium antibody). Sections were
then treated simultaneously with biotinylated-donkey anti-rabbit
antibody and tetramethylrhodamine isothiocyanate (TRITC)-
conjugated goat anti rat antibody (Jackson Immunoresearch
Laboratories, PA, USA) for 1 h at room temperature. Finally,
ALEXA488-conjugated streptavidin (Molecular Probes, Leiden,
The Netherlands) and TRITC-conjugated donkey anti-goat anti-
bodies were applied for another 1 h at room temperature.
Hypoxic regions and vessel signals were then scanned to overlay
the initial Hoechst image and composite binary images produced.
Vessel density was calculated from the total number of vessels
divided by the tumour area (excluding any appreciable areas of
necrosis, determined from haematoxylin and eosin staining).
Perfused vessels were identiﬁed as those where Hoeschst 33342
and 9F1 signals overlapped. The perfused fraction (PF) was
calculated by dividing the area of perfused vessels by the total
vascular area.
Radiation treatment
Mice were restrained but unanaesthetized during this procedure.
Control and E2-treated tumours that had attained 200 mm
3 were
locally irradiated with a single dose of 15 Gy delivered at
2 Gy min
71 and allowed to grow to three times the size at the
time of treatment. The time taken for each tumour to double in
volume from treatment size (TD) was obtained from the log phase
of growth. In all treatment groups, regression analysis to calculate
r
2 values conﬁrmed a linear relationship. To make statistical
comparisons between the response of the tumours with or without
E2-treatment, the speciﬁc growth delay (SGD) was calculated for
each tumour using the following equation:
SGD 
TDtreated ÿ TDcontrol
TDcontrol
1
TDcontrol represents the initial doubling time of the untreated
tumours calculated from growth rate attained during exponential
growth phase for each tumour type (Bailey et al, 1980; Kopper
and Steel, 1975). Hence, the SGD values represent the number of
TDs saved by the radiation treatment.
Statistical analysis
All the numerical data from analysis between the different treat-
ment groups were expressed as mean value+1 standard
deviation (s.d.). Tumour doubling times (TD) were calculated
from the log phase and linear regression analysis was performed
to conﬁrm a linear relationship. Statistical comparisons of differ-
ences in mean tumour measurements after treatment between
groups were carried out using a two-way analysis of variance
(ANOVA) followed by an unpaired Student’s t-test. Signiﬁcance
was achieved if P50.05.
RESULTS
Effect of E2-treatment on tumour growth rate and NOS
activity
The effect of E2-treatment on the growth of MDA231 tumours was
studied either with treatment commencing prior to tumour
implantation (Figure 1) or on matched tumours that had attained
a size of about 200 mm
3 (Figure 2). E2-treatment prior to tumour
implantation signiﬁcantly enhanced the tumour growth rate with
TD values of 7+0.7 days compared to 12+1.3 days for control
tumours (Table 1). When E2-treatment was administered to mice
bearing established tumours, the growth rate of these tumours were
again increased (TD of 7.0+1.3 days compared to 12+1.3 days for
control). Hence, E2-treatment did not only increase the onset of
tumour growth but also increased the growth rate of established
tumours. This increase in tumour growth rate following E2-treat-
ment was accompanied by at least a 4–5-fold induction of iNOS
activity as determined by the conversion of L-[
14C]-arginine to L-
[
14C]-citrulline (Table 2).
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Figure 1 Growth of MDA231 breast tumours in mice. Animals were
treated with E2 (*) (1.7 mg, 60-day sustained release pellets), E2 plus L-
NAME (!), L-NAME alone (~) and no treatment (&). Tumour doubling
(TD) times from these treatment groups were obtained from the log phase
of growth. Calculated r
2 values from linear regression analysis were 0.981,
0.984, 0.953 and 0.995 for control, E2-treatment alone, E2-treatment with
L-NAME, and L-NAME alone, respectively.
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Figure 2 Effect of E2 on growth of established MDA231 breast tumours.
Tumours were allowed to grow to approximately 150 mm
3 and half of
sized-matched tumours were either treated with E2 (~) (1.7 mg, 60-day
sustained release pellets) or left untreated (*). : indicates point at which
E2-treatment was commenced.
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Also represented in Figure 1 (and included in Table 1) is growth
delay data following prophylactic treatment with L-NAME. A rela-
tionship was apparent between NOS activity expression and
tumour growth. Treatment with L-NAME abolished the growth
promoting effect by E2 (Figure 1). This was evident from TD values
of 12.7+3.0 and 11.4+0.5 days for L-NAME treatment alone or in
combination with E2, respectively and these values were not differ-
ent from those of untreated tumour-bearing mice (12.0+1.3 days).
ER measurements in xenografts
Results obtained from ER measurements showed levels for both
control and E2-treatment groups were below the sensitivity limits
of the monoclonal system used which was 1.5 fmol ER mg
protein
71 (Table 2). Based on this information, tumours obtained
from both experimental groups were judged to be ER-negative.
Immunohistochemistry
Conﬁrmation of in situ localization of NOS in tumours utilized a
rabbit polyclonal antibody for iNOS. The results obtained (Figure
3) show positive staining for NOS across all treatment groups
particularly in the endothelium of blood vessels and some connec-
tive tissue cells. A weaker staining of tumour cells was observed in
controls. However, in the E2-treatment group, there was consistent
localisation of NOS expression (intense staining) in a region
between ‘viable’ tumour cells and true necrotic regions.
Analysis of tumour hypoxia, vessel density and perfusion
Multiparameter analysis for tumour hypoxia, vessel density and
extent of perfusion were carried out on tumours that had reached
200 mm
3. The results obtained (Table 3) suggested that E2-treated
tumours presented with an elevated hypoxic fraction and lower
vessel density when compared to those in the control group. In addi-
tion, the E2-treated tumours were characterized by a lower fraction
of perfused vessels. Despite these trends, the difference in hypoxic
fraction between control and E2-treated tumours was found not to
be statistically signiﬁcant at 5% level of signiﬁcance (P50.05).
Tumour radiation response
To assess the therapeutic consequences of the altered growth
response by E2-treatment, a single radiation dose of 15 Gy was
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Table 1 Tumour doubling time (TD) in days following E2 and L-NAME
treatments
Treatment group TD (days)
Control untreated 12.0+1.3
E2 post implant (at 150 mm
3) 7.0+1.3
a
E2 before tumour implant 7.0+0.7
a
L-NAME 12.7+3.0
L-NAME+E2 11.0+0.5
TD was calculated from growth rate attained during exponential growth phase, as
outlined in the text. Values+s.d. from at least ﬁve animals per experimental group.
aSigniﬁcantly different from control and L-NAME treated groups.
Table 2 NOS activity levels and ER status in MDA 231 tumours
NOS activity
(pmol
14C-citrulline formed min
71 mg
71)
Treatment Calcium-independent ER status
group Total (iNOS) (fmol mg
71)
E2 treatment 2.62+0.68
a 2.08+0.45 51.5
Control 0.54+0.10 0.42+0.10 51.5
NOS activity was measured by monitoring the conversion of L-[U-
14C]-arginine to L-
[U-
14C]-citrulline and ER determination employed a monoclonal antibody kit, as out-
lined in the text. Data are mean+s.d. from triplicate determinations for at least four
tumours per group.
aSigniﬁcantly different from control group (P50.05).
Figure 3 In situ localization of iNOS in MDA231 breast tumour. A primary anti-iNOS polyclonal antibody was applied on control (A) and E2-treated (B)
tumour sections (for details see Materials and methods’). Haematoxylin was used as a nuclear counterstain. Following incubation with a biotinylated bridging
and an avidin-biotin complex labelled horseradish peroxidase, positive staining for the presence of iNOS was seen as a dark brown end-product after
incubation with 3,3-diaminobenzidine hydrochloride (DAB) as a substrate.
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3 in size. SGD
data was calculated for each treatment group when tumours
attained three times treatment size. The data presented (Table 3)
shows that E2-treated tumours were more radio-resistant compared
to untreated tumours. This was reﬂected in SGD values of 2.9+0.1
and 5.7+0.2, for E2-treated tumours and control, respectively.
DISCUSSION
The physiological and clinical signiﬁcance of hormonal modulation
of the growth of human breast cancer cells in vivo are often difﬁ-
cult to interpret presumably as a result of the lack of host-related
determinants that affect tumour behaviour. Growth of solid
tumours is often regulated by interactions of endothelial cells of
the tumour vasculature, tumour-inﬁltrating immune cells such as
T-lymphocytes and macrophages, as well as the tumour cells them-
selves. It is known that E2 can increase the expression of NOS in a
range of normal tissues (Weiner et al, 1994). In addition, some
studies have shown that exposure to E2 may be associated with
an increased incidence of breast cancer (Nenci et al, 1988). Our
results demonstrate that long term E2-treatment of the putatively
ER-negative human breast adenocarcinoma cell line MDA231,
causes a substantial elevation in endogenous NO levels by modulat-
ing NOS expression. Signiﬁcantly, E2-treated tumours in mice grew
at a faster rate than their untreated counterparts and this is in
agreement with studies carried out by others (Friedl and Jordan,
1994; Friedl et al, 1989). Prophylactic treatment with the NOS
inhibitor, L-NAME, abolished this apparent E2-mediated growth
stimulation. These results strongly implicate NO in mediating this
increased growth response seen with the MDA 231 tumours receiv-
ing E2-treatment.
Conﬁrmation of NOS expression in tumour sections was further
illustrated by employing a polyclonal antibody against iNOS on
tumour sections. Although positive staining for NOS occurred in
all the treatment groups, it was observed that the E2-treatment
group showed intense localization of iNOS in viable tissue, particu-
larly in areas interfacing with necrotic tissue (i.e. regions that are
hypoxic). Therefore, the actual NOS activity and consequently
NO production within this tumour sub-population, could be much
higher than our estimation of NOS activity using whole tumour
homogenate. The observed NOS staining in tumour sections was
reminiscent of that seen with in situ detection of iNOS mRNA
expression in the human colon adenocarcinoma cell line, DLD-1
(Jenkins et al, 1995). These ﬁndings suggest that E2-stimulated
increase in iNOS activity may be co-ordinately mediated by the
presence of hypoxia. Hypoxia responsive elements (HREs) found
within a number of genes involved in energy metabolism and
angiogenesis can speciﬁcally regulate transcription response to
tumour hypoxia (O’Rourke et al, 1997). Moreover, hypoxia has
been shown to regulate endothelial mitogens such as VEGF and
platelet-derived endothelial cell growth factor (PD-ECGF) in
tumour cells (Minchenko et al, 1994). It is also known that the
promoter region of the iNOS gene contains a multiplicity of
consensus sequences for the binding of transcription factors,
including the HRE, thus rendering the iNOS gene hypoxia-
inducible (Melillo et al, 1995). Therefore, in tumours NOS activity
can be dependent on the level of hypoxia and E2.
Several hypotheses have been put forward to explain the
mechanistic basis of E2 action as a tumour growth promoter in
ER-negative carcinomas. Rapid tumour growth could be accounted
for as either due an increase in cell proliferation, or a decrease in
cell loss (apoptosis). We propose that low and sustained NO
production due to E2-treatment in our tumour model provides
the angiogenic signal that leads to enhanced tumour cell prolifera-
tion. Human tumours in immunodeﬁcient host animals represent a
complex model; steroid hormones modulate the residual immune
system, inﬂuence the endocrine milieu and alter the stroma. E2-
treatment could enhance tumour growth by modulating the host
to produce other growth factors (McGuire et al, 1975). Conversely,
growth of cells within the tumour mass may be affected by inter-
actions between malignant cells and the surrounding stroma. An
inﬂuence of stromal ﬁbroblasts on the growth of breast carcinoma
cells has been demonstrated in vivo (Gleiber and Schiffman, 1984).
It has also been proposed that insulin-like growth factors that act
synergistically with E2 on breast cells, may also be produced by
stromal cells (Yee et al, 1989; van der Burg et al, 1990). Depending
on its concentration, the biological redox milieu and the involve-
ment or induction of intracellular defence mechanisms, NO can
either suppress apoptosis and eventually stimulate proliferation
or activate the cell death programme (Lopez-Farre et al, 1998).
There have been studies carried out indicating that exposure to
E2 may cause perturbation of the apoptotic pathway and may be
associated with tumourigenesis (Carson and Ribeiro, 1993;
Mikulski, 1994).
Another area that has received considerable attention in provid-
ing a mechanistic basis for E2 growth stimulation, has been the role
of NK cell activity. It is widely believed that NK cells have an
important role in immune surveillance against tumours (Heberman
and Holden, 1979; Talmadge et al, 1980). A number of studies have
linked suppression of NK activity with chronic administration of
E2 (Kozlowski et al, 1984; Seaman et al, 1978; Shakhar and Ben-
Eliyahu, 1998) and reduced NK activity has been associated with
increased metastatic potential of different human cell lines in athy-
mic mice (Kozlowski et al, 1984). The role of NK suppression is
debatable and several other workers have systematically found a
lack of correlation between NK cell activity and tumour growth
(Fodstad et al, 1984, Friedl and Jordan, 1994).
Initial studies on MDA231 cells ER status led to the understand-
ing that these cells lacked the ability to transcribe the ER gene
(Weigel and deConnick, 1993), now known as ER-alpha (ER-a).
More recently, another ER isoform has been identiﬁed known as
ER-be that is highly homologous to ER-a, particularly in the
DNA-binding and ligand binding domains (Dechering et al,
2000). Variant forms of ER-b have been identiﬁed that are co-
expressed with wild-type ER-b in MDA231 breast cancer cells
(Fuqua et al, 1999; Leygue et al, 1999; Vladusic et al, 1998,
2000). In addition, available data suggests that changes in the rela-
tive expression of mRNAs for certain types of ER-a and ER-b
might occur during breast tumourigenesis and tumour progression
(Leygue et al, 1998; Pujol et al, 1998). It is therefore difﬁcult to
completely exclude the possibility that low and undetectable levels
of ER in MDA231 tumour cells may cause growth stimulation via
the classic ER-mediated pathway.
The interdependence between NO and hypoxia is believed to
play an important role in controlling tumour growth and radiation
response. Studies employing NO donor agents have shown that NO
sensitizes hypoxic cells to ionizing radiation (Mitchell et al, 1993).
It has been postulated that the mechanism for enhanced radiosen-
sitivity by NO is presumably due to the rapid reaction between
radiation-induced carbon centre radicals on DNA with NO thereby
‘ﬁxing’ the damage (Howard-Flanders, 1957). It is known that the
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Table 3 Vessel density, perfused fraction, hypoxic fraction and radiation
response of MDA 231 tumours
Treatment Vessel Perfused Hypoxic Speciﬁc growth
group density mm
2 fraction fraction delay (SGD)
Control 51+12 0.59+0.02 0.067+0.03 5.7+0.20
E2 37+11
a 0.33+0.08
a 0.093+0.23 2.9+0.10
a
Vessel density was evaluated utilizing a speciﬁc endothelial antibody. Similarly, per-
fused and hypoxic fractions were evaluated by employing speciﬁc markers, as out-
lined in the text. Both experimental groups received the same radiation dose of
15 Gy delivered at 2 Gy min
71. The SGD values represent the number of TDs
saved by the radiation treatment. Data represent mean+s.d. obtained from three
tumours per group excised at time of radiation treatment.
aSigniﬁcantly different
from control (P50.05).
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tion against challenges from subsequent higher concentrations
(Kim et al, 1995). Therefore, the adaptation of hypoxic cells to
spontaneous short-term NO release, such as by NO donor agents,
may be different to those seen in cells that are exposed to low and
sustained levels of NO generated endogenously during tumour
growth. The latter situation would provide these tumour cells with
a selective survival advantage over untreated cells when exposed to
radiation dose. E2-treated tumours were signiﬁcantly more radio-
resistant when compared to control tumours. In conclusion, the
observed alterations in the radiation response due to long term
E2-treatment, would suggest that the level of circulating hormone
should be taken into consideration in determining the timing
and outcome of radiation therapy, particularly to breast cancer
patients.
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